KYMR vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELAN
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.
Kymera Therapeutics vs.
Kymera Therapeutics (NASDAQ:KYMR) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Qiagen received 194 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 60.29% of users gave Qiagen an outperform vote while only 53.40% of users gave Kymera Therapeutics an outperform vote.
Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Qiagen had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Qiagen and 3 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.00 beat Qiagen's score of -0.37 indicating that Kymera Therapeutics is being referred to more favorably in the media.
70.0% of Qiagen shares are held by institutional investors. 15.8% of Kymera Therapeutics shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Kymera Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
Kymera Therapeutics currently has a consensus price target of $55.06, suggesting a potential upside of 49.59%. Qiagen has a consensus price target of $47.71, suggesting a potential upside of 20.73%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kymera Therapeutics is more favorable than Qiagen.
Qiagen has a net margin of 4.23% compared to Kymera Therapeutics' net margin of -191.26%. Qiagen's return on equity of 13.92% beat Kymera Therapeutics' return on equity.
Summary
Qiagen beats Kymera Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYMR) was last updated on 2/21/2025 by MarketBeat.com Staff
Free KYMR Stock Alerts